Learn More
The problem of predicting gene locations in newly sequenced DNA is well known but still far from being successfully resolved. A novel approach to the problem based on the frame dependent (non-homogeneous) Markov chain models of protein-coding regions was previously suggested. This approach is, apparently, one of the most powerful "search by content"(More)
OBJECTIVE As of 3 September 2013, 399 cases of natalizumab-associated progressive multifocal leukoencephalopathy (PML) were confirmed in multiple sclerosis (MS) patients. We evaluated outcomes of natalizumab-treated MS patients who were asymptomatic at PML diagnosis. METHODS Analyses included data available as of 5 June 2013. Asymptomatic patients(More)
Natalizumab, a highly effective therapy for relapsing-remitting multiple sclerosis, is associated with a risk of progressive multifocal leukoencephalopathy (PML). The objective of this analysis was to examine factors predicting survival in a large natalizumab-associated PML global population. Patients with natalizumab-associated PML identified through(More)
This paper is supposed to bridge the gap between practical experience in using GeneMark for a rapidly widening repertoire of genomes, and the available publications that determine and compare the gene prediction accuracy of the GeneMark method for different genomes. Here we focus on the genome-specific variability of prediction error rates and their(More)
  • 1